48 results about "Tumor angiogenesis" patented technology

The invention discloses application of a tripterygium wilfordii exosome in preparation of an anti-cervical cancer medicine and a tumor angiogenesis inhibiting medicine, and relates to the field of biological medicine. The medicinal plant exosome derived from tripterygium wilfordii is successfully separated, and it is proved that the medicinal plant exosome can regulate related pathways through delivery of functional nucleic acid molecules to inhibit proliferation and migration of cervical cancer cells and promote active oxygen related apoptosis so as to be used for tumor treatment. The tripterygium wilfordii exosome can further act on vascular endothelial cells in a tumor microenvironment, the migration function of Hela cells is inhibited, and then the effect of resisting cell proliferation in the tumor microenvironment is achieved. The tripterygium wilfordii exosome has the advantages of being simple in preparation method, remarkable in tumor growth resistance and tumor cell migration inhibition effect, good in biocompatibility, high in delivery efficiency and the like, and can be used as a novel nano-drug for tumor treatment.

The invention provides a broad-spectrum combined medicine for treating colorectal cancer. The broad-spectrum combined medicine is prepared from the following components in parts by weight: 100 parts of purified water, 38 to 90 parts of tripterygium wilfordii alkaloid, 38 to 90 parts of tripterygium hypoglaucum alkaloid, 28 to 85 parts of chamaejasmine, 28 to 85 parts of gelsmium elegans alkaloid and 28 to 85 parts of xanthoxylin. The medicine is prepared from the following raw materials in parts by weight: 16 to 80 parts of ganoderan, 16 to 80 parts of pinellia ternate sitosterol, 16 to 80 parts of radix rehmanniae praeparata, 16 to 80 parts of astragaloside, 16 to 80 parts of oldenlandia diffusa alkaloid, 16 to 80 parts of sculellaria barbata alkaloid, 16 to 80 parts of tanshinone, 16 to 80 parts of carthamin, 16 to 80 parts of honeysuckle chlorogenic acid and 16 to 80 parts of pericarpium citri reticulatae flavone. By integrating anti-tumor components with multiple action mechanisms, tripterygium wilfordii alkaloid, tripterygium hypoglaucum alkaloid and the like, tumor cell proliferation can be directly inhibited, and apoptosis can be induced; tanshinone, emodin and the like can inhibit tumor angiogenesis; ganoderma lucidum polysaccharides, astragaloside and the like can activate the immune system of the body, enhance the activity of T cells and NK cells, and form double strikes of direct killing and immune surveillance.

This invention belongs to the pharmaceutical field, specifically relating to an anti-tumor angiogenesis drug potentiator, an anti-tumor drug composition, and its application. Firstly, this invention discovers that SHCBP1 inhibitors can enhance the therapeutic effect of anti-tumor angiogenesis drugs and can be used as potentiators for anti-tumor angiogenesis drugs. Secondly, when SHCBP1 inhibitors are used in combination with anti-tumor angiogenesis drugs, or in combination with anti-tumor angiogenesis drugs and PD-1 inhibitors, tumor angiogenesis can be normalized and its window period prolonged, significantly improving the efficacy of immunotherapy, anti-angiogenesis, and anti-tumor therapy, showing broad application prospects.

The present invention relates to the field of biomedicine and specifically relates to an anti-VEGF-anti-PD-L1 bispecific antibody, a pharmaceutical composition of same, and uses thereof. Specifically, the present invention relates to the bispecific antibody, which comprises: a VEGF-targeted first protein functional area and a PD-L1-targeted second protein functional area, wherein: the first protein functional area is an anti-VEGF antibody or an antigen-binding fragment thereof, or, the first protein functional area comprises a VEGF receptor or a fragment having a VEGF receptor function, and the second protein functional area is an anti-PD-L1 monoclonal antibody. The bispecific antibody of the present invention is capable of activating the immune system and blocking tumor angiogenesis at the same time, and provides great antitumor prospects.

The invention discloses an application of an esterase response cationic polymer in preparation of an anti-tumor immunotherapy drug. The esterase response cationic polymer is an esterase response cationic polymer containing (p-phenolic ester group) benzyl amine or (p-phenolic ester group) benzyl ester. The compound can kill tumor cells, induce immunogen cell death (ICD), promote the tumor cells to release tumor-associated antigens, induce antigen-presenting cells to gather in tumors and present tumor antigens, activate killer T cells, inhibit tumor neovascularization, improve the tumor microenvironment, inhibit tumor cell apoptosis, inhibit tumor cell apoptosis, inhibit tumor cell apoptosis and inhibit tumor cell apoptosis after intratumor injection. Therefore, the organism obtains the anti-tumor immunity capability.

The present disclosure provides use of Clostridium ghonii combined with a tumor angiogenesis inhibitor in preparing a pharmaceutical product for treating a tumor. The present disclosure further provides a drug for treating a tumor, where the drug includes active ingredients of Clostridium ghonii and a tumor angiogenesis inhibitor.

The invention relates to a construction method of a perfusion vascularized cervical cancer organoid chip, and relates to the technical field of biology. Comprising the following steps: S1, constructing a cervical cancer organ; s2, mixing the cervical cancer organ small cell cluster, the human umbilical vein endothelial cells and the human embryonic lung fibroblasts in proportion, and centrifugally gathering the mixed cells in a low-adsorption U-shaped plate to form a pre-vascularized cervical cancer organ; s3, re-suspending the pre-vascularized cervical cancer organoid and the human umbilical vein endothelial cells in the fibrous protein hydrogel, transferring the pre-vascularized cervical cancer organoid and the human umbilical vein endothelial cells into the organoid chip, and adding a vascularized cervical cancer organoid culture medium for culture, so that the endothelial cells form perfused blood vessels, and finally obtaining the perfused vascularized cervical cancer organoid chip. The prepared perfusion vascularized cervical cancer organoid can well solve the in-vitro vascularization problem of the organoid, simulates the in-vivo tumor angiogenesis process, is close to the in-vivo real tumor microenvironment, and provides technical support for exploration of cervical cancer disease mechanisms and related treatment.

The present application relates to the technical field of RPS4X, and particularly relates to siRNA targeting RPS4X gene, LAMB3-PI3K-AKT signal pathway inhibitor, ovarian cancer drug and application. The siRNA targets and interferes with RPS4X gene expression. The siRNA and the LAMB3-PI3K-AKT signal pathway inhibitor are used on in-vitro ovarian cancer cells and in-vivo ovarian cancer tissues, and both have the effect of inhibiting proliferation, migration and invasion. The various siRNAs targeting RPS4X gene and the LAMB3-PI3K-AKT signal pathway inhibitors provided in the embodiments have the effects of promoting apoptosis of ovarian cancer cells and tissues and inhibiting tumor angiogenesis, have obvious ovarian cancer prevention and treatment effects, and have the application prospect of developing as ovarian cancer drugs.

Provided is the use of clostridium ghonii in combination with a tumor angiogenesis inhibitor in the preparation of a pharmaceutical product for treating tumors. Further provided is a drug for treating tumors, and active ingredients of the drug comprise the clostridium ghonii and the tumor angiogenesis inhibitor.

The present application provides a derivative with a repaglinide tetravalent platinum structure and a preparation method and use thereof, the compound with the repaglinide tetravalent platinum structure is shown as general formula (I), wherein, selected from cisplatin or oxaliplatin; L is hydroxyl or a series of repaglinide platinum (IV) compounds targeting p53 pathway described in the present application, which shows good anti-proliferation and anti-metastasis activity in vitro and in vivo. The severe DNA damage caused by platinum core can up-regulate the expression of p53, and repaglinide (RPG) can also effectively promote the secretion of p53 through the lumican / p53 / p21 pathway. The present application designs and synthesizes a series of repaglinide tetravalent platinum derivatives, which can start mitochondrial-mediated apoptosis through the Bcl-2 / Bax / caspase-3 pathway. Subsequently, with the up-regulation of p53, the compound can effectively activate pro-apoptotic autophagy, inhibit the epithelial-mesenchymal transition (EMT) process, and then inhibit tumor angiogenesis by inhibiting COX-2, MMP9 and VEGFA. The compound can also increase the number of CD3 + And CD8 + T cells in tumors by blocking immune checkpoint PD-L1, and stimulate anti-tumor immunity. The above multiple anti-tumor mechanisms synergistically inhibit the proliferation and metastasis of tumor cells.

The invention belongs to the technical field of medicines, and particularly relates to an application of oleanolic acid in tumor resistance, and the application of oleanolic acid in tumor resistance specifically comprises the following steps: inhibiting tumor cell proliferation and inducing apoptosis; tumor angiogenesis is inhibited; the drug resistance of tumor cells is reversed; the immune function is regulated, and the anti-tumor immunity is enhanced; tumor invasion and metastasis are inhibited; according to the method, supercritical CO2 extraction is adopted, recoverable CO2 is used as an extraction medium, and no toxic organic solvent such as chloroform is used in the whole process; a small amount of ethanol is used only in the links of resin activation and elution, and is recovered through vacuum concentration, so that the use amount is extremely small, the treatment is easy, and the environmental pollution caused by solvent leakage or residue is avoided from the source.

The invention discloses an apatinib-immune synergistic nano-drug based on bacterial source vesicles as well as a preparation method and application of the apatinib-immune synergistic nano-drug. The nano-drug is Apatinib-MVs, and the nano-drug takes a membrane vesicle secreted by parabacteroides coumarini as a carrier to entrap an anti-angiogenesis drug apatinib; in-vitro anti-tumor experiment results show that the nano-drug can exert an efficient anti-tumor effect through a dual synergistic mechanism of inhibiting tumor angiogenesis and activating anti-tumor immune response at the same time.

The invention discloses a cytochalasin compound with an anti-tumor effect as well as a preparation method and application of the cytochalasin compound. The compound disclosed by the invention is derived from a fermentation product of a cynanchum chinense endophytic fungus Aspergilusizukae RD-16. The compound disclosed by the invention has the advantages that the compound can be used for preparing the cynanchum chinense endophytic fungus; the compound has remarkable cytotoxic activity to various tumor cells and almost has no toxicity to normal colonic epithelial cells. Meanwhile, the compound also has an effect of inhibiting angiogenesis. A Western Blot experiment result proves that the compound activates the expression of tumor cell autophagy related protein by inhibiting a PI3K-AKT-mTOR signal channel and induces tumor cells to generate autophagy; on the other hand, by inhibiting expression of angiogenesis related protein p-VEGFR2, tumor angiogenesis is blocked, and the anti-tumor effect is synergistically enhanced through multiple paths. The compound has potential application in preparation of novel anti-tumor drugs, and provides scientific basis for research and development of novel anti-tumor drugs.

The invention relates to an anti-cancer composition based on natural active ingredients and a medicine thereof, and belongs to the technical field of medicine compositions. The anticancer composition based on the natural active ingredients is prepared from the following components in percentage by mass: 1 to 10 percent of ginsenoside Rg3, 5 to 20 percent of dihydroquercetin, 20 to 40 percent of lucid ganoderma extract, 15 to 30 percent of astragalus extract and 15 to 30 percent of coix seed extract. In the anti-cancer composition based on the natural active ingredients, ginsenoside Rg3 has the effect of inhibiting tumor angiogenesis; the dihydroquercetin has remarkable antioxidant and anti-inflammatory activity; ganoderma lucidum polysaccharide can enhance the immune function of the body. Astragaloside has an immunoregulation effect; coix seed ester has the anti-tumor metastasis activity, the anti-cancer effect is remarkably enhanced through the synergistic effect of multiple components, toxic and side effects are low, the composition is suitable for long-term taking, and the product quality is stable.

In combination with conventional therapies (e.g., targeted therapy, chemotherapy, and angiogenesis inhibitors etc.), immunotherapies targeting checkpoint molecules have shown promise in the treatment of solid or liquid tumors. However, apoptotic regulatory T cells (Treg) induced by such therapies often become more suppressive in the tumor microenvironment (TME), through increased generation of adenosine tightly controlled by ectonucleotidases, viz. CD39 and CD73. CD39 / ENTPD1, a novel checkpoint molecule, is highly expressed and activated on the tumor vasculature and infiltrating immune cells, promoting tumor growth. Deletion or blockade of CD39 enhances anti-tumor activity by augmenting anti-tumor immune responses and inhibiting tumor angiogenesis. The present invention is based at least in part on the development of anti-CD39 antibodies which mediate CD39 downregulation on immune cells, such as T-cells with markers of T-cell exhaustion, and the demonstrated utility of these antibodies in blocking tumor growth with minimal side effects in pre-clinical models.

The invention relates to the technical field of preparations for treating thyroid cancer patients, in particular to application of an iodine-containing composition in preparation of products for treating thyroid cancer. At present, a specific guidance scheme about the optimal iodine intake does not exist for patients with differentiated thyroid cancer (DTC), especially patients with structural persistent lesions after surgery and / or radioiodine treatment. In China, although definite evidences are lacked, a large number of patients still select lifelong low-iodine diets and try to avoid iodine-induced relapse. The application of the invention overcomes prejudice and proves that low-iodine diet can promote biochemical progress of thyroid cancer on the contrary, and iodine-suitable diet can better help patients with differentiated thyroid cancer to recover, inhibit RYR1 gene expression and weaken tumor angiogenesis and cell migration ability, thereby inhibiting tumor progress.

The invention discloses ingenol methyl crotonate and application of a composition containing the ingenol methyl crotonate in preparation of medicines for treating tumors, and belongs to the field of biological medicines. The ingenol methyl crotonate can inhibit formation of vascular mimicry after treatment of tumor vascular inhibition drugs, and is combined with nimotuzumab and other tumor vascular inhibition drugs for use to inhibit drug resistance of the tumor vascular inhibition drugs and further inhibit recurrence and metastasis of nasopharyngeal carcinoma, so that the survival rate of nasopharyngeal carcinoma patients is increased, the prognosis of the nasopharyngeal carcinoma patients is improved, and the nasopharyngeal carcinoma patients are promoted. Important clinical significance and industrial popularization and application prospects are realized.

The invention relates to the technical field of traditional Chinese medicine compositions, and discloses a traditional Chinese medicine compound composition for adjuvant therapy of cancers and a preparation method thereof. Comprising the following traditional Chinese medicine components in parts by weight: 5-10 parts of scorpio, 10-20 parts of royal jelly freeze-dried powder, 5-15 parts of ginseng, 10-20 parts of rhizoma polygonati, 10-30 parts of astragalus membranaceus, 5-15 parts of dendrobium officinale, 10-20 parts of rehmannia, 5-15 parts of lucid ganoderma, 10-30 parts of oldenlandia diffusa, 10-20 parts of radix ophiopogonis, 5-15 parts of dogwood, 10-20 parts of codonopsis pilosula, 5-15 parts of liquorice, 0.1-0.5 part of selenium yeast, 5-15 parts of edible tulip, 10-20 parts of hawthorn, 5-15 parts of chrysanthemum and 10-30 parts of dandelion. And 3-10 parts of cinnamon. The scorpion, the pseudobulbus cremastrae seu pleiones and other components can directly inhibit tumor cell proliferation and induce apoptosis; the selenium yeast can scavenge free radicals and inhibit tumor angiogenesis. The royal jelly freeze-dried powder, the ginseng, the astragalus membranaceus, the lucid ganoderma and the like can activate immune cells, improve the immune monitoring ability of a body and relieve immunosuppression caused by radiotherapy and chemotherapy.

The application provides sulfated derivatives of fucosylated chondroitin sulfate oligosaccharides and application thereof, and belongs to the technical field of marine drugs. The structure of the sulfated derivatives of fucosylated chondroitin sulfate oligosaccharides is mainly a disaccharide repeating unit with GlcA and GalNAc connected through a beta-1,3 / beta-1,4 glycosidic bond as a main chain, and a fucose connected to the O-3 position of GlcA as a side chain; sulfation occurs at any 1-3 positions of C4 and / or C6 of the acetylglucosamine in the main chain, and C2,3,4 of the fucose in the side chain. Through in-vivo and in-vitro level verification, the application plays an anti-tumor metastasis role by significantly inhibiting the adhesion of tumors to endothelium, platelets and the like and tumor angiogenesis, so as to use S-dFCS as an active substance, prepare a medicine or a health product with the aid of a pharmaceutically acceptable carrier, and be capable of being used for preventing and treating tumors and diseases related to postoperative metastasis.

The invention belongs to the technical field of biological medicine, and relates to application of PARVA as a target spot in lung cancer prevention and treatment. Specifically, the invention provides application of PARVA in preparation of drugs for treating or preventing lung cancer and application of PARVA in reagents or kits for diagnosis or prognosis evaluation of lung cancer. The invention further provides a lung cancer treatment medicine or a lung cancer prevention medicine taking PARVA as a target spot and a kit which comprises a reagent for detecting PARVA mRNA or protein expression and is used for lung cancer diagnosis or lung cancer prognosis evaluation. The invention provides application of PARVA as a target spot in prevention and treatment of lung cancer, and lung cancer cell proliferation, invasion and metastasis and tumor angiogenesis are inhibited by regulating and controlling expression or functions of PARVA in lung cancer cells and tumor microenvironment, so that effective treatment, early diagnosis, recurrence prevention and prognosis evaluation of lung cancer are realized.

The application belongs to the technical field of medicine, and particularly relates to a ginsenoside Rb2 composition for lung cancer adjuvant treatment and a preparation method thereof. The composition comprises the following components: ginsenoside Rb2, black chicken mushroom polysaccharide and snakeroot alkaloid; the mass ratio of the ginsenoside Rb2, the black chicken mushroom polysaccharide and the snakeroot alkaloid is 1: (0.2-0.5): (0.03-0.08). The composition can effectively induce tumor cell oxidative stress and apoptosis, and simultaneously inhibit tumor angiogenesis by scientific compounding of three active ingredients to synergistically exert the anti-lung cancer effect from multiple targets and mechanisms.

The application discloses a kind of tumor angiogenesis simulation methods, including the blood vessel network topology including environment pixel point and blood vessel pixel point generated based on the medical image of patient;Based on the average path length and step length adjustment factor, chemotaxis weight, bifurcation number range and bifurcation probability of related data such as blood vessel tip of blood vessel network topology are constantly updated;And the bifurcation number of each iteration blood vessel tip and the branch length of each branch after bifurcation are calculated based on the update result of each iteration, and the update of blood vessel network topology is completed based on the bifurcation number and the branch length of each branch after bifurcation calculated, constantly circulate until reaching simulation condition.The application quantifies the transport efficiency of blood vessel network by global function index average path length, realizes the evaluation whether blood vessel network presents efficient local characteristics by clustering coefficient and average path length, guarantees that the blood vessel network obtained by simulation is same with real network.

The invention discloses application of an organic selenium compound in preparation of anti-tumor angiogenesis drugs. The anti-tumor angiogenesis activity of selenium compounds (inorganic selenium, organic selenium and selenium nanoparticles) in different forms is compared by the system, the effect of organic selenium is most prominent, and the organic selenium can effectively induce active oxygen mediated apoptosis and cell cycle arrest of human umbilical vein endothelial cells (HUVECs). The organic selenium is used as a lead compound for drug design, and a good reference is provided for developing novel high-efficiency and low-toxicity anti-tumor angiogenesis drugs.

This invention relates to polypeptides, specifically to a PD-1 and αvβ3 bifunctional polypeptide and its applications, the amino acid sequence of which is shown in SEQ ID NO.1. The PD-1 / αvβ3 bifunctional polypeptide can simultaneously inhibit the PD-1 / PD-L1 pathway and the αvβ3 pathway, not only inhibiting tumor growth and invasion and suppressing abnormal tumor angiogenesis, but also promoting immune cell infiltration into tumors by blocking the PD-1 pathway, inhibiting angiogenesis, and regulating PD-L1 expression, thereby modulating the tumor microenvironment and exerting a synergistic immune effect.

The invention belongs to the technical field of medicines, and relates to a traditional Chinese medicine effective component composition for intervening osteosarcoma angiogenesis, which is composed of astragaloside and curcuma zedoary general flavone in a mass ratio of (1-4): 1. The effective component composition has a remarkable curative effect on tumor angiogenesis and regulation and control of osteosarcoma proliferation, growth and metastasis, all the components are natural effective monomer components, no hormone component or toxic or side effect exists, the composition is more easily absorbed by the human body, and no burden is caused to the liver and the kidney.

An indazole hydrazide compound, as represented in formula (I); wherein, R is selected from substituted alkyl, substituted alkenyl and substituted phenyl; substituent in the substituted alkyl and substituted alkenyl includes phenyl and / or substituted phenyl; R′ is selected from H and alkyl. Compared with the prior art, the above indole hydrazide compound can be used as integrin avβ3 receptor antagonist. Besides, it has obvious anti-prostate cancer activity and has a significant inhibitory effect on enzalutamide-resistant cell lines. In addition, the above-mentioned compound has obvious anti-tumor angiogenesis activity and can be used in the preparation of anti-tumor angiogenesis drugs to inhibit tumor angiogenesis.

In various embodiments of the present disclosure, compositions comprising anti-MYCT1 antibodies and methods for modulating MYCT1 activity are provided. One embodiment of the present disclosure provides a method for controlling tumor angiogenesis and / or anti-tumor immunity (which inhibit tumor growth) in a subject.

The present invention discloses the application of cytochrome c oxidase subunit 4 isoform 2 (COX4I2) in the preparation of a predictive biomarker for the prognosis and immunotherapy responsiveness of human colorectal cancer patients. The present invention evaluated the correlation between COX4I2 levels and clinical characteristics and their biological effects in vitro and in vivo, and found that elevated COX4I2 levels were associated with poor prognosis in colorectal cancer patients. Experimental studies also observed that COX4I2 could participate in the epithelial-mesenchymal transition (EMT) of colorectal cancer cells, promote the expression of fibroblast growth factor 1 (FGF1), activate and recruit tumor-associated fibroblasts, and promote tumor angiogenesis. Therefore, COX4I2 can be used as a biomarker for the prognosis of colorectal cancer patients and may also be a new target for therapeutic development.

The invention is in the field of medicine. More specifically, it is in the field of diagnosing tumor angiogenesis status and in the field of medical treatment of a subject who is suffering, suspected to suffer, or might suffer from a tumor in the future. In particular, the invention relates to a fusion polypeptide comprising a foreign antigen and a self antigen, wherein said foreign antigen consists of a polypeptide comprising an amino acid sequence of at least 12-15 amino acid residues, 12-24% of which residues are hydrophilic, bulky amino acid residues selected from the group consisting of histidine, glutamate, arginine, glutamine, aspartic acid and / or lysine.

The application discloses an NGR peptide coupled ruthenium complex and a preparation method and application thereof, and belongs to the technical field of tumor photodynamic therapy. The application couples NGR peptide and a two-photon active ruthenium complex to construct a double-targeted photosensitizer. The NGR oligopeptide can specifically combine with CD13 receptors which are highly expressed on the surface of tumor vascular endothelial cells and tumor cells, realize double targeting of'vessel+tumor cell', and significantly improve the tumor enrichment efficiency of drugs. The NGR peptide coupled ruthenium complex provided by the application can efficiently generate active oxygen under the excitation of 820 nm near-infrared light, specifically kill CD13 positive target cells, and the tissue penetration depth can reach 250 microns, which is suitable for deep tumor treatment. Meanwhile, the NGR peptide coupled ruthenium complex can efficiently destroy the pipe forming ability of vascular endothelial cells, and significantly inhibit tumor angiogenesis.